Mitomycin C, 5Fluorouracil and Folinic Acid in Combination with Alpha 2b Interferon for Advanced Colorectal Cancer
| Autor: | Romeo Bascioni, R. R. Silva, Simonetta Rossini, Tullio Battelli, Mazzanti P, Nicola Battelli, Alberta Pilone, Rodolfo Mattioli, Stefano Delprete, Manocchi P |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Colorectal cancer Mitomycin Leucovorin Interferon alpha-2 Gastroenterology Drug Administration Schedule Folinic acid Interferon Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged business.industry Mitomycin C Interferon-alpha General Medicine Middle Aged medicine.disease Recombinant Proteins Regimen Treatment Outcome Oncology Toxicity Female Fluorouracil Bolus (digestion) Colorectal Neoplasms business Progressive disease medicine.drug |
| Zdroj: | Tumori Journal. 79:393-396 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089169307900604 |
| Popis: | Aims and Background This study was conducted to investigate the activity and toxicity of 5fluorouracll + folinic acid + mitomycin C combined with alpha 2b Interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5 fluorouracil by interferon. Patients and methods Between June 1990 and April 1991 25 previously untreated patients with advanced colorectal carcinoma were treated with mitomycin C 10 mg/m2 iv bolus on day 1, 5fluorouracil 375 mg/m2 on days 1 to 4 and folinic acid 200 mg/m2 on days 1 to 4 every 4 weeks, combined with alpha 2b interferon 3 million U day continuously. Response Of the 25 patients entered into the study, 20 were evaluable for response as 5 patients withdrew due to toxicity (grade 3-4 thrombocytopenia in 4 cases and fatigue in 1). No complete response was recorded, 6 patients had partial remission (30 %; 95 % confidence interval, 10 % to 50 %), 4 experienced no change and 10 showed progressive disease. The toxicity of this regimen was significant, particularly myelosuppression. Conclusions This combination showed a significant toxicity and low response rate compared with other 5 fluorouracil based regimens in advanced colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|